Saturday 17 October 2026
Export QNRX’s income statement to Excel — free account
Quoin Pharmaceuticals, Ltd. Sponsored ADR
QNRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 69.8% and free cash flow fell 510.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.90
0.13
−3.23%
Follow QNRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.61 | 3.57 | 3.15 | 3.79 | 1.79 | 0.06 | 5.11 | 3.80 | 6.97 | 9.30 |
Net Debt/EBITDA |
1.16 | 1.49 | 1.15 | 1.40 | 1.26 | (0.57) | 0.81 | 0.62 | 1.15 | 1.98 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.06% | 1.86% | 0.00% | 0.00% | 0.17% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.18) | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.86 | 0.88 | 0.91 | 0.90 | 0.27 | 0.64 | 1.21 | 1.18 | 0.63 | 0.94 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (2.40) | (6.01) | (2.09) | (0.27) | (1.43) | (0.72) | (3.34) |
Interest Coverage |
— | 17.06 | 13.50 | (12.96) | (4.44) | (35.53) | (15.20) | (1,300.50) | (6.28) | (460.67) |
| (141.59%) | (120.56%) | (132.92%) | (234.30%) | 721.40% | 181.08% | (121.45%) | (117.27%) | (126.74%) | (78.87%) | |
| (87.56%) | (64.30%) | (65.25%) | (79.33%) | (399.87%) | (55.53%) | (83.30%) | (75.23%) | (92.62%) | (65.07%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(109.30%) | (83.41%) | (112.75%) | (95.98%) | (592.55%) | 27.86% | (103.56%) | (131.71%) | (109.41%) | (50.56%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.05 | 0.05 | 0.09 | 0.66 | 0.16 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(12.68) | (59.62) | (304.82) | (1,505.29) | (7,931.37) | (2,592.67) | (59,180.00) | (1.00) | (0.93) | (0.89) |
Cash per Share |
17.55 | 106.65 | 414.53 | 2,216.12 | 9,353.50 | 539.67 | 52,390.00 | 0.73 | 1.43 | 1.77 |
Shareholders Equity per Share |
12.28 | 69.84 | 219.53 | 1,277.03 | 821.25 | (11,012.17) | 42,930.00 | 0.57 | 0.97 | 1.63 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.28 | 69.84 | 219.53 | 1,277.03 | 821.25 | (11,012.17) | 42,930.00 | 0.57 | 0.97 | 1.63 |
Free Cash Flow |
(13.54) | (7.86) | (7.86) | (8.73) | (6.35) | (1.56) | (5.92) | (6.48) | (5.20) | (4.05) |
Working Capital |
14.46 | 10.75 | 7.70 | 9.84 | 3.62 | (7.52) | 4.32 | 3.66 | 7.05 | 7.52 |
Capital Expenditures |
— | — | — | (0.25) | (0.62) | (0.22) | (0.03) | (0.17) | (0.08) | (0.30) |
Net Current Asset Value |
12.74 | 8.42 | 4.78 | 6.32 | (0.50) | (7.52) | 3.50 | 3.18 | 4.91 | 7.02 |
| Other line items | ||||||||||
Quick Ratio |
3.38 | 3.36 | 2.99 | 3.64 | 1.64 | 0.04 | 5.11 | 3.80 | 6.97 | 9.30 |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.30 | 0.28 | 0.25 |
Cash ROIC |
(42.49%) | (33.78%) | (48.07%) | (43.09%) | (77.95%) | 30.68% | (61.35%) | (76.54%) | (38.72%) | (26.19%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(12.68) | (59.62) | (304.82) | (1,462.19) | (7,150.12) | (2,231.00) | (58,840.00) | (0.97) | (0.92) | (0.82) |
Capex per Share |
0.00 | 0.00 | 0.00 | (43.10) | (781.25) | (361.67) | (340.00) | (0.03) | (0.01) | (0.07) |
Average Receivables |
— | — | — | — | — | 0.11 | 0.18 | 0.23 | 0.31 | 0.24 |
Average Payables |
1.08 | 0.72 | 0.57 | 0.76 | 0.52 | 0.08 | 0.14 | 0.36 | 0.43 | 0.24 |
Average Assets |
18.05 | 13.94 | 13.31 | 11.91 | 5.37 | 3.77 | 5.84 | 7.13 | 8.79 | 6.12 |
Average Common Equity |
11.16 | 7.43 | 6.54 | 4.03 | (2.98) | (1.16) | 4.00 | 4.58 | 6.42 | 5.05 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates